7/10/2007 11:39:49 AM
WALTHAM, Mass.--(BUSINESS WIRE)--Epitome Biosystems announced today a second licensing and development agreement with EMD Chemicals Inc., an affiliate of Merck KGaA of Germany, using Epitome’s EpiTag™ technology. The partnership will focus on developing EpiTag™ assays for the quantitative measurement of various targets, including membrane proteins. Products will be manufactured, marketed and sold worldwide for research applications by EMD through its well-known Novagen® brand. Sample analysis will be available as a service from Epitome. Terms of the agreement were not disclosed.
comments powered by